上海市锦天城律师事务所 关于上海睿昂基因科技股份有限公司 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 11、12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务 所 法律意见书 上海市锦天城律师事务所 关于上海睿昂基因科技股份有限公司 法律意见书 致：上海睿昂基因科技股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受上海睿昂基因科技股份有 限公司（以下简称"公司"）委托，就公司召开 2024 年年度股东大会（以下简称"本 （以下简称"《公司法》"）、 次股东大会"）的有关事宜，根据《中华人民共和国公司法》 《上市公司股东会规则》等法律、法规和其他规范性文件以及《上海睿昂基因科 技股份有限公司章程》 （以下简称"《公司章程》"）的有关规定，出具本法律意见 书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用原则，对本次股东大会所涉及的相关事 项进行了必要的核查和验证，核查了本所认为出具该法律 ...

湖北日报全媒记者 杨然 通讯员 袁野 "没有荷枪实弹的飒爽英姿，没有惊心动魄的短兵相接，在安静的实验室里，剪刀是我的利剑，白大褂 是我的铠甲，仪器上滚动的数据是我拨开迷雾查明真相的密码。" 这是吴玉剑博士给自己的职业寄语。 吴玉剑是武汉市公安司法鉴定中心负责DNA检验鉴定的专家型民警。他不像刑侦民警那样冲锋在抓捕 罪犯的一线，却用最前沿的科技，为侦破案件指明方向。 从警9年来，吴玉剑利用DNA技术直接认定犯罪嫌疑人500余名，破获多起大案要案。 一次招警公告改变他的人生轨迹 吴玉剑是生物学科班出身。2003年，他考入东北师范大学生物学专业。4年后，这个四川小伙进入中国 科学院大学，硕博连读。2013年毕业后，他被聘请到光谷一家基因检测公司，专门从事以高通量DNA 测序技术为基础，开发癌症风险评估、优生优育等相关基因检测产品。 由于能力突出，吴玉剑很快被提拔为技术主任、实验室主任，还被派往国外接受业务培训，逐步成长为 公司业务高管。 但一次偶然看到的招警公告，改变了吴玉剑的人生轨迹。 2016年初，武汉市公安局发布公告，希望引进一名具有DNA技术相关专业博士学位的人才。吴玉剑看 到后，萌生巨大兴趣："我从小就喜 ...

记者 吴卫群 见习记者 高晨辉 本届上交会由深圳市担任境内主宾城，总部位于深圳的华大基因携"GenSIRO-16灵曦高通量基因检 测AI+本地化解决方案"参展。在欧洲、美洲、亚太等地区，华大基因与超过3000家海外医疗和科研机 构建立了合作关系，同时在全球范围内与近400家精准医学实验室有合作。展位负责人表示："我们为临 床提供的医学检测服务构建了'覆盖全国、辐射全球'的网络布局，业务范围遍及全球100多个国家和地 区。" "十四五"以来，上海技术进出口合同金额年均增长8.6%。2024年，上海技术进出口合同金额为 213.3亿美元，同比增长17.7%，创历史新高，居全国各省区市首位。本届上交会开幕当天，商务部国际 贸易经济合作研究院发布了《全国技术贸易创新实践案例》，上海有多项成果入选。 随团而来的英国格拉斯哥毕克气体首次亮相上交会，带来实验室气体制备绿色解决方案。"我们的 氢气发生器可现场制备实验室所需氢气，通过'即产即用'模式替代传统运输罐装气体，不仅消除运输环 节的碳排放，更以闭环系统提升操作安全性。"展位负责人告诉记者，此次参展，企业不仅希望将最新 气体生成技术引入中国市场，更期待通过技术合作，为中 ...

Core Viewpoint - BGI Genomics has officially established a strategic partnership with the Shenzhen Data Exchange, launching its first comprehensive tumor database, marking a significant step towards transforming into a data-driven intelligent medical ecosystem [2][9]. Group 1: Strategic Cooperation - The partnership aims to deepen collaboration in key areas such as data product innovation, industry data standard construction, data compliance and security, financialization of data assets, and data space development [2]. - BGI Genomics is transitioning from a traditional genetic testing service provider to a data-driven intelligent medical ecosystem, leveraging its proprietary platform and technological advantages to build a comprehensive database reflecting the genetic characteristics of the Chinese population [9][11]. - The cooperation is seen as a critical move to construct an autonomous data ecosystem and implement the national strategy of "data elements × healthcare" [9]. Group 2: Industry Context - The global precision medicine market is experiencing rapid growth, and China's data element market reform is making significant breakthroughs, with Shenzhen leading the way by establishing a data exchange and regulatory framework for compliant data circulation [4][5]. - The collaboration is positioned as a key starting point for the value development of genetic data, aiming to explore innovative paths for compliant development and application of genetic data [11]. - The initiative addresses critical industry challenges such as data security, privacy protection, and complex regulatory compliance, providing a systematic framework to enhance overall governance in the sector [13]. Group 3: Product Launch - BGI Genomics has launched a gene data product, the comprehensive tumor database, which integrates authoritative global genetic variation and treatment data while focusing on clinical guidelines and practice data unique to China [13]. - This product aims to provide high-value data services for precision medicine research and alleviate challenges associated with reliance on international databases [13].

Summary of GeneDx Conference Call Company Overview - GeneDx was established 25 years ago at the National Institutes of Health, focusing on diagnosing difficult cases, particularly in rare diseases [4][5] - The company has built the largest rare disease data asset in the U.S., with over 800,000 exomes and genomes and more than 6,100,000 phenotypic data points [5][6] Strategic Initiatives - GeneDx aims to reduce the diagnostic odyssey, which currently takes about five years, to weeks or even hours [5][6] - The company is focusing on increasing utilization in pediatric outpatient settings and NICUs [6] Differentiation and Market Position - GeneDx's tests are differentiated by their extensive data assets, which include a highly representative database and a robust phenotypic data set [7][8] - Approximately 60% of the time, both parents are tested, enhancing the accuracy of diagnoses [7] - The company claims an 80% market share among expert geneticists, with significant growth potential in pediatric neurology and NICU settings [14][16] Market Penetration - In pediatric neurology, GeneDx has only penetrated about 14% of the patient population, indicating substantial growth opportunities [16] - In NICUs, fewer than 5% of babies currently receive genetic testing, despite studies showing that 60% would benefit from it [19][22] - GeneDx aims to increase its NICU testing to approximately 225,000 tests annually, targeting a quarter million children by 2026-2027 [24] Product Development and Testing - GeneDx has launched a two-day ultra-rapid turnaround time for genome testing, which is expected to enhance market uptake [25][26] - The company is expanding its testing indications to include conditions like cerebral palsy and hearing loss, focusing on the best clinical outcomes [29][30] Financial Performance and Cost Management - GeneDx has achieved profitability and aims for continued profitable growth, focusing on areas with sufficient reimbursement [17][18] - The company has reduced denial rates from 65% to less than 50% for pediatric neurologists, improving reimbursement rates and gross margins [48][49] - Current gross margins for exome and genome testing are around 80%, with ongoing efforts to reduce costs further through automation and technology [54][56] Future Growth and Market Strategy - GeneDx plans to expand into adult genetic testing as reimbursement pathways develop, aiming for early diagnosis across all age groups [62][63] - The company is also exploring monetization of its extensive data set for biopharma, aiming to contribute to drug discovery and clinical trial development [64][66] Conclusion - GeneDx is positioned as a leader in genetic testing for rare diseases, with a strong focus on data-driven diagnostics and expanding market opportunities in pediatric and adult settings. The company is committed to improving patient outcomes through faster and more accurate testing while maintaining a focus on profitability and cost management.

此外，本届上交会还设置技术交易服务和技术交易促进活动2个功能区域，总展出面积为3.5万平方米， 汇聚了来自全球近20个国家和地区及国内近20个省区市的创新成果。英国格拉斯哥市担任境外主宾城， 深圳市担任境内主宾城。展会期间将举办1场开幕式、3场主题日活动和近60场配套活动。 自2013年首次举办以来，上交会在推动技术进口来源多元化、支持成熟的产业化技术出口、拓展国际技 术合作网络等方面发挥了重要作用。数据显示，上交会累计吸引来自30多个国家和地区超9500家企业参 展，近两届意向成交项目数均超500项。 上海市商务委主任朱民表示，本届上交会技术特色更突出，将展示一批长三角共性技术研发和关键领域 核心技术突破的成果。粤港澳大湾区将展示交互型机器人、基因检测设备等领域的创新成果。首次设立 的智能海洋工程与装备展区，彰显上海优势产业特色与领先性。本届上交会首次设立消费与商业科技展 区。另外，展会还将推出一批生产性互联网服务平台、绿色航贸数链等领域工作成果。 据统计，本届上交会共有高新技术企业、专精特新企业、瞪羚企业180家。朱民表示，战略性新兴产业 方面，本届上交会将全面展示"AI+"跨行业解决方案，如人工智能多模 ...

硅谷知名基因检测公司23andMe在经历破产风波三个月后，迎来了戏剧性的转折。 | Product | | --- | | Total revenue | | Cost of revenue: | | Service (includes related party cost of nil for both the three morths ended December 31, 2024 and 2023 and nil and $295 for the nine months ended December | | Product | | Total cost of revenue | | Gross profit | | Operating expenses: | | Research and development | | Sales and marketing | | General and administrative | | Restructuring and other charges | | Goodwill impairment | | Total operating expenses | | ...

本报讯(记者张宣)近日，世和基因肿瘤早筛学术成果暨"金陵队列"研究数据发布会在南京举行。记者从 发布会上了解到，由世和基因主导的DECIPHER-Omnia万例多癌早筛研究成果已于5月29日发表于国际 顶级期刊《自然医学》上。 公开数据显示，目前我国每天确诊癌症的患者中，有80%的患者初诊已是中晚期，错过了最佳治疗时 期。癌症早筛早诊早治对挽救生命、减轻家庭和社会经济负担具有重要意义。目前癌症筛查方式普遍存 在侵入性强、依从性差、准确率低等缺陷，且推荐范围主要覆盖肺癌、乳腺癌、结直肠癌等少数癌种。 针对这一临床痛点，世和基因历经五年潜心研发，采用超低深度全基因组测序，联合AI专用大模型， 全面分析血液中游离的cfDNA片段大小、分布等多维特征，从中发现肿瘤特有信号，成功推出 MERCURY无创血检多癌早筛技术，仅需一管血即可筛查9种高发癌症，并能准确溯源患癌部位，从而 协助临床进行诊疗。 2022年，世和基因联合南京江北新区、南京医科大学共同发起肿瘤早筛公益科研项目"金陵队列"，目前 已为近1.5万名南京居民提供了2.5万人次全套免费体检。研究数据显示，相关检测特异性(真阴性率)为 98.1%，灵敏性(真阳性 ...

Group 1 - The core viewpoint of the news is that Berry Genomics has experienced a decline in its financial performance, with significant drops in both revenue and net profit in the latest quarterly report [1] - As of the first quarter of 2025, Berry Genomics reported a revenue of 218 million yuan, representing a year-on-year decrease of 22.08% [1] - The company's net profit for the same period was a loss of approximately 6.46 million yuan, which is a year-on-year decline of 178.47% [1] Group 2 - Berry Genomics' stock closed at 15.3 yuan, marking an increase of 4.51%, with a latest price-to-book ratio of 3.24, which is the lowest in 49 days [1] - The total market capitalization of Berry Genomics is approximately 5.409 billion yuan [1] - The company has 10 institutional investors holding a total of 84.94 million shares, with a combined market value of 1.149 billion yuan [1] Group 3 - The main business of Berry Genomics focuses on high-throughput sequencing technology and related genetic testing services, including reproductive health genetic testing and hereditary disease testing for children and adults [1] - The average price-to-earnings (P/E) ratio for the industry is 50.80, while Berry Genomics has a negative P/E ratio of -26.11 [2] - The industry median price-to-book ratio is 2.48, while Berry Genomics' price-to-book ratio stands at 3.24 [2]

Group 1 - The core business of the company includes gene testing, mass spectrometry testing, bioinformatics analysis, and medical AI models, providing comprehensive solutions for research services, precision medical testing, and health management [2] - The company has received multiple awards, including the "2023 Chinese Preventive Medicine Association Science and Technology Award" and recognition in the ESG field for its management practices [2] - The latest financial report shows a revenue of 672 million yuan for Q1 2025, a year-on-year decrease of 18.18%, and a net loss of approximately 52.7 million yuan, with a gross profit margin of 43.55% [3] Group 2 - As of May 29, the company's stock closed at 52.26 yuan, up 3.83%, with a latest price-to-book ratio of 2.39 and a total market capitalization of 21.731 billion yuan [1] - On May 29, the company experienced a net inflow of main funds amounting to 13.51 million yuan, with a total inflow of 57.99 million yuan over the past five days [1] - The company's price-to-earnings ratio (TTM) is -22.45, indicating a negative earnings performance compared to the industry average of 49.64 [3]